Stockscreener 앱 받기
25.50
2.75%
-0.72
시간 외 거래:
25.50
전일 마감가:
$26.22
열려 있는:
$26.04
하루 거래량:
1.56M
Relative Volume:
0.93
시가총액:
$4.37B
수익:
$1.10B
순이익/손실:
$375.65M
주가수익비율:
11.61
EPS:
2.1963
순현금흐름:
$113.59M
1주 성능:
-1.05%
1개월 성능:
+20.91%
6개월 성능:
-3.63%
1년 성능:
+21.54%
1일 변동 폭
$25.30
$26.04
1주일 범위
$25.30
$26.51
52주 변동 폭
$19.69
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
25.50 | 4.49B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-23 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? - Yahoo Finance
Acadia rises as EU backs Rett syndrome therapy - MSN
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value? - Yahoo Finance
Why Acadia Pharmaceuticals stock is soaring today - MSN
ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win? - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change? - simplywall.st
How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors - Yahoo Finance
H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Carl Segerstrom Appointed Chief People Officer at Acadia Pharmaceuticals - hrtoday.in
Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative? - Sahm
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating - Moomoo
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer - BioSpace
ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News & Headlines - Yahoo Finance
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief Talent Officer - GuruFocus
Acadia taps 25-year HR veteran for chief people officer role - Stock Titan
ACADAcadia Pharmaceuticals Inc Forecast, Target Price - Finviz
Understanding the Setup: (ACAD) and Scalable Risk - Stock Traders Daily
Price to sales forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD - TradingView
Price to book forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD - TradingView
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
Price to earnings forward of ACADIA Pharmaceuticals Inc. – BIVA:ACAD - TradingView
Price to book forward of ACADIA Pharmaceuticals Inc. – LSX:603035 - TradingView
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results - Investing.com
ACAD stock eyes best day in over a year as CHMP recommends approval for rare nerve disorder drug in Europe - MSN
ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now - TMX Newsfile
ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds - simplywall.st
ACAD Maintains Buy Rating -- Price Target Raised to $30.00 by B of A Securities - GuruFocus
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $30 to $37 - Moomoo
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress - Investing.com Australia
ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup - Moomoo
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia Pharmaceuticals principal accounting officer sells $297,912 - Investing.com UK
Acadia Pharmaceuticals principal accounting officer sells $297,912 By Investing.com - Investing.com Nigeria
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Nigeria
ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan - Stock Titan
ACAD stock up as CHMP backs Daybu for EU approval in Rett syndrome - MSN
ACAD Maintained by Canaccord Genuity -- Price Target Raised to $36.00 - GuruFocus
ACAD Maintained by Citigroup -- Price Target Raised to $35 - GuruFocus
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome - The Globe and Mail
EMA reverses its stance on Acadia’s Rett syndrome therapy Daybu - BioWorld News
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus - Seeking Alpha
Acadia Pharmaceuticals (ACAD) Receives Positive CHMP Opinion for DAYBU Approval - GuruFocus
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus (NASDAQ:ACAD) - Seeking Alpha
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating - marketscreener.com
Canaccord raises Acadia Pharmaceuticals price target on EU approval By Investing.com - Investing.com Canada
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - BioSpace
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acadia Pharmaceuticals Inc 주식 (ACAD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 26 '26 |
Sale |
21.18 |
5,401 |
114,393 |
24,509 |
5.60%
0.04%
자본화:
|
볼륨(24시간):